The global asparaginase market size was USD 648.6 Million in 2021 and is expected to register a robust CAGR of 16.7% during the forecast period. Key factors driving market revenue growth are increasing population, rapid urbanization, and growing income in several countries. However, side effects associated with asparaginase may limit its adoption and thus, hinder market revenue growth to some extent.
Asparaginase is an enzyme, and it is used in industries, such as food, pharmaceutical, and others. In the pharmaceutical industry, it is used to manufacture chemotherapy drugs to treat leukemia and its types, and it is derived from two types of bacteria – Escherichia coli (E.coli) and Erwinia chrysanthemi. Rising incidences of leukemia among people across the world and increasing innovations in the biopharmaceutical industry are expected to boost revenue growth of the global asparaginase market. Furthermore, a growing biopharmaceutical industry in emerging countries is expected to generate significant growth opportunities in the market.
Request a Sample@ https://www.qyresearchmedical.com/sample/119116
Asparaginase is most commonly used as a processing aid in the food industry to reduce formation of acrylamide, a suspected carcinogen, in starchy food items, such as snacks, biscuits, and fried potatoes. When potato slices are pre-treated with asparaginase before frying, the acrylamide content in the processed chips is reduced by up to 81% compared to untreated chips. Acrylaway and Preventase are two popular brand names for asparaginase.
However, revenue growth of the market can be significantly hampered by several unfavorable factors, such as side effects associated with asparaginase, which include pancreatitis, mild bone marrow suppression, and risks of blood clotting and stroke. Nevertheless, increasing incidence of acute lymphocytic leukemia is expected to create growth opportunities for the global asparaginase market over the forecast period. Jazz Pharmaceuticals, Shire, Medac GmbH, and Kyowa Hakko Kirin are considered to be the leading players in this industry. They have high-end customer bases and key technologies and patents, and are, therefore, set to remain at the forefront of the industry in the upcoming years.
Driver: Growing Pharmaceutical Industry and Increasing Focus on Research & Development (R&D)
Asparaginase market participants are investing in research & development, as well as production of asparaginase, to meet regulatory specifications and rising product demand. In addition, increasing number of FDA approvals is expected to drive revenue growth of the market in years to come. On June 30, 2021, the Food and Drug Administration (FDA) approved a new form of asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze), which was developed to address the ongoing shortage of Erwinia asparaginase. Rylaze was approved as part of a treatment regimen for children and adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL), a rare but aggressive cancer that resembles ALL.
In addition, in February 2022, Jazz Pharmaceuticals plc announced to complete the submission of a Supplemental Biologics License Application (sBLA) to the FDA seeking approval for a intramuscular (IM) dosing schedule for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase. Development of such new products and their approval is expected to play a significant role in revenue growth of the global market.
Restraints: Side Effects Associated with Asparaginase
Common side effects of asparaginase injections include allergic reactions, pancreatitis, blood clotting problems, high blood sugar, kidney problems, and liver dysfunction. Furthermore, use of this injection in pregnancy may harm the baby. The most common adverse reactions of asparaginase erwinia chrysanthemi (recombinant)-rywn include abnormal liver tests, nausea, musculoskeletal pain, fatigue, infection, headache, pyrexia, drug hypersensitivity, febrile neutropenia, decreased appetite, stomatitis, bleeding, and hyperglycemia. Such side effects associated with asparaginase can restrict its adoption and thus, hamper growth of the global market to a certain extent.
Based on source, the global asparaginase market is segmented into Erwinia chrysanthemi and Escherichia coli. The Escherichia coli segment is expected to account for largest revenue share in the global market during the forecast period. Asparaginase derived from E. coli has been clinically shown to exhibit antitumor actions in models of leukemias. L-asparaginase of E. coli is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections.
Asparaginase preparations derived from E. coli are the most widely used forms of asparaginase, and prior studies have highlighted their importance in the treatment of childhood ALL. However, a significant percentage of patients develop allergic symptoms during treatment with native E. coli asparaginase.
Based on application, the global asparaginase market is segmented into acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). The acute lymphoblastic leukemia (ALL) segment is expected to account for largest revenue share over the forecast period. Asparaginase is one of the most important chemotherapeutic agents against pediatric acute lymphoblastic leukemia, the most common form of childhood cancer. The risk for developing ALL is highest in children younger than 5 years of age. According to data published by the American Cancer Society in 2021, nearly 5,690 new cases of ALL were reported in the U.S. Increasing prevalence of acute lymphoblastic leukemia is expected to drive revenue growth of this segment over the forecast period.
Route of Administration Outlook:
Based on the route of administration, the global market is segmented into intramuscularly and intravenously. Intravenously segment accounted for largest revenue share in 2021 and is expected to register a significantly faster revenue growth rate during the forecast period. Intravenous injection is a type of injection that delivers a drug into a vein. The needle is inserted into a vein, and then the drug is directly delivered into the bloodstream, which is the fastest way of administering medications. Since the drug enters the bloodstream immediately, it takes effect faster in comparison to intramuscular administration. However, there exist concerns over increasing incidence of infusion-related reactions associated with this administration method compared to intra muscular delivery.
The intramuscular route of administration is a technique used to deliver medications deep into the muscles. Muscles are rich in blood vessels and hence, absorption of the drug is faster when it is delivered intramuscularly. Moreover, intramuscular injections are less invasive, and can be done in less time and have a large injection site (a muscle) compared to intravenous injections. These advantages are expected to increase adoption of intramuscular administration of drugs and thereby, allow this segment to register a significantly fast growth rate over the forecast period.
Age Group Outlook:
Based on age group, the global market is segmented into pediatric and adult. The pediatric segment is expected to lead in terms of revenue share over the forecast period, owing to growing prevalence of acute lymphoblastic leukemia in pediatric patients. Acute lymphoblastic leukemia is the most common cancer in pediatric patients, with overall 5-year survival rates for children diagnosed with ALL exceeding 90%. The length of treatment for these patients is typically 2 to 3 years and involves several phases (induction, consolidation, and maintenance) and multiple forms of chemotherapy.
The adult segment is expected to register a slower revenue growth rate as compared to pediatric segment, as the prevalence of acute lymphoblastic leukemia cancer is less in adults. According to the American Cancer Society, about 4 out of every 10 cases of ALL are in adults.
Distribution Channel Outlook:
Based on distribution channel, the global asparaginase market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment is expected to account for largest revenue share during the forecast period. Increasing prescription of medications at hospitals due to more frequent diagnoses at these institutes is the key factor expected to drive revenue growth of this segment.
The online pharmacy segment is expected to register the highest revenue CAGR, owing to rising popularity of online pharmacy due to the ease and convenience provided by it. The retail pharmacy segment is expected to account for a significantly large revenue share during the forecast period. Presence of a small number of retail pharmacies offering products in developing countries is expected to drive revenue growth of this segment during the forecast period.
Based on regional analysis, North America accounted for largest revenue share in 2021 and is expected to maintain its leading position in the global market over the forecast period. Revenue growth of this regional market is being driven by rising prevalence of leukemia. According to the American Cancer Society estimates, there were approximately 61,090 new cases and 23,660 deaths from leukemia in the U.S. in 2021. Furthermore, expansion of the pharmaceutical industry owing to presence of key market players in the region and high demand for a variety of food and beverages with added enzymes, such as asparaginase, are expected boost market revenue growth in North America.
Europe is expected to account for a significantly large revenue share between 2021 and 2030. Countries such as Germany, the U.K., and France are major revenue contributors in this region. An increasing number of patients with acute lymphocytic leukemia in Europe is expected to boost demand for asparaginase. According to Cancer Research U.K., there are around 790 new acute lymphoblastic leukemia cases in the U.K. every year. Thus, high prevalence of lymphoblastic leukemia is expected to play a major role in revenue growth of the Europe market.
The Asia-Pacific asparaginase market is expected to register the fastest revenue CAGR over the forecast period. In developing countries, such as India, China, Malaysia, and Indonesia, prevalence of various chronic diseases is increasing, which is expected to drive market revenue growth. Additionally, government bodies of these countries are investing huge sums in the asparaginase market to encourage pharmaceutical companies to utilize the product for treating chronic illnesses, which is also expected to support revenue growth of the Asia-Pacific market over the forecast period.
The global asparaginase market is competitive with several emerging and well-established key players. Various strategies such as mergers, acquisitions, or collaborations are being incorporated by these market players to maintain a strong footing in the market. Some major companies included in the market report are Jazz Pharmaceuticals (Ireland), Medac GmbH (Germany), Taj Pharmaceuticals Ltd. (India), LGM Pharma (U.S.), Actiza Pharmaceutical Pvt. Ltd. (India), Gennova Biopharmaceuticals (Emcure Pharma) (India), Kyowa Hakko Kirin Co., Ltd. (Japan), Merck (Germany), Servier Pharmaceuticals LLC (France), and Novus Biologicals LLC (U.S.).
Recent Market Development
· In June 2021, Jazz Pharmaceuticals plc announced the U.S. Food and Drug Administration approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen, for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma, in adults and pediatric patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase.
Segments Covered in the Report
This report offers historical data points and forecasts and revenue growth at a global, regional, and country-level, and provides analysis, industry trends, and consumption pattern details for each region, major country, and segment from 2022 to 2030.
For this report, Reports and Data has segmented the global asparaginase market based on source, application, route of administration, age group, distribution channel, and region:
Asparaginase Market Report Scope
Segments covered By Source Outlook, Application Outlook, Route of Administration Outlook, Age Group Outlook, Distribution Channel Outlook, Regional Outlook
By Source Outlook
By Application Outlook
Acute Lymphoblastic Leukemia (ALL)
Lymphoblastic Lymphoma (LBL)
By Route of Administration Outlook
By Age Group Outlook
By Distribution Channel Outlook
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://www.qyresearchmedical.com/report/checkout/119116/1500
You can place an order or ask any questions, please feel free to contact firstname.lastname@example.org | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: